Identification

Listing sponsor / Agent

FORTIS

Symbol
OCTO
ISIN code
NL0000345718
Trading location
Amsterdam
ICB
Biotechnology
Activity description

The issuer was founded in 1995 and is a product-oriented biopharmaceutical company committed to the development of improved pharmaceutical products that are based on proprietary drug delivery technologies of the company and have fewer side effects, increased patient convenience and better efficacy than existing therapies.

Website address
http://www.octoplus.nl/index.cfm/octoplus

Operation

IPO date
Mo. 03/12/2007
IPO type

Introduction by public issue of new shares

IPO type
Initial Public offering
Catégorie
IPO
Operation description

Offering of up to 4,9 million newly issued ordinary shares, at a price range of EUR 4,65 to EUR 5,50 per Share.

Operation calendar

Date of first listing: 4 October 2006 Settlement: 9 october 2006

Company profile

OctoPlus is a drug delivery company specialized in the development of improved pharmaceutical products that are based on OctoPlus' proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. In addition, the group is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients. Net sales break down by source of income as follows: sales of services (99.6%) and licensing revenues (0.4%). Net sales are distributed geographically as follows: Europe (34.9%), North America (24.3%) and other (40.8%).

Source: Cofisem - Last Update: 05 Mar 2013
Key Executives
Chief Executive Officer Jan Hendrik Egberts
Chief Financial Officer Susan Swarte
Communications Rianne Roukema
Investor Relations Rianne Roukema
Source: Cofisem - Last Update: 04 Jul 2012
Key figures
Millenium 2011 2010 2009 2008 2007
Net sales 7.702 8.329 19.046 16.923 5.194
Income from ordinary activities 7.702 8.329 19.046 16.923 5.194
Operating income -5.436 -5.221 -1.800 -4.202 -15.134
Cost of net financial indebtedness -880 -981 -1.160 -1.640 -33
Equity-Accounted companies' contribution to results
Net profit from discontinued activities
Net income -6.316 -6.202 -2.957 -6.209 -15.175
Net income (group share) -6.316 -6.202 -2.957 -6.209 -15.175
Fiscal year end 12,11 12,10 12,09 12,08 12,07
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards Exercices aux normes IAS-IFRS à compter de l'exercice 2004. Exercices aux normes IAS-IFRS à compter de l'exercice 2004. Exercices aux normes IAS-IFRS à compter de l'exercice 2004. Exercices aux normes IAS-IFRS à compter de l'exercice 2004. Exercices aux normes IAS-IFRS à compter de l'exercice 2004.
Source: Cofisem - Last Update: 05 Mar 2013
Shareholder information
Dr. Reddy's Laboratories Ltd 98,61 %
Source: Cofisem - Last Update: 04 Mar 2013